These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 36757612)

  • 1. NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease.
    Han QQ; Le W
    Neurosci Bull; 2023 May; 39(5):832-844. PubMed ID: 36757612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
    Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T
    Front Immunol; 2021; 12():719807. PubMed ID: 34691027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Haque ME; Akther M; Jakaria M; Kim IS; Azam S; Choi DK
    Mov Disord; 2020 Jan; 35(1):20-33. PubMed ID: 31680318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
    Gordon R; Albornoz EA; Christie DC; Langley MR; Kumar V; Mantovani S; Robertson AAB; Butler MS; Rowe DB; O'Neill LA; Kanthasamy AG; Schroder K; Cooper MA; Woodruff TM
    Sci Transl Med; 2018 Oct; 10(465):. PubMed ID: 30381407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.
    Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE
    J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease.
    Wang S; Yuan YH; Chen NH; Wang HB
    Int Immunopharmacol; 2019 Feb; 67():458-464. PubMed ID: 30594776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
    Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
    J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment.
    Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q
    Front Immunol; 2021; 12():794770. PubMed ID: 34925379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia.
    Pike AF; Varanita T; Herrebout MAC; Plug BC; Kole J; Musters RJP; Teunissen CE; Hoozemans JJM; Bubacco L; Veerhuis R
    Glia; 2021 Jun; 69(6):1413-1428. PubMed ID: 33506583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NLRP3 Inflammasome in Parkinson's Disease and Therapeutic Considerations.
    Nguyen LTN; Nguyen HD; Kim YJ; Nguyen TT; Lai TT; Lee YK; Ma HI; Kim YE
    J Parkinsons Dis; 2022; 12(7):2117-2133. PubMed ID: 35988226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
    Si XL; Fang YJ; Li LF; Gu LY; Yin XZ; Jun-Tian ; Yan YP; Pu JL; Zhang BR
    Exp Neurol; 2021 Feb; 336():113525. PubMed ID: 33161049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1/Parkin pathway.
    Wang A; Zhong G; Ying M; Fang Z; Chen Y; Wang H; Wang C; Liu C; Guo Y
    Neuropharmacology; 2024 Oct; 257():110063. PubMed ID: 38972372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
    Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW
    J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.
    Kou L; Chi X; Sun Y; Han C; Wan F; Hu J; Yin S; Wu J; Li Y; Zhou Q; Zou W; Xiong N; Huang J; Xia Y; Wang T
    J Neuroinflammation; 2022 Jun; 19(1):133. PubMed ID: 35668454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications.
    Soraci L; Gambuzza ME; Biscetti L; Laganà P; Lo Russo C; Buda A; Barresi G; Corsonello A; Lattanzio F; Lorello G; Filippelli G; Marino S
    J Neurol; 2023 Mar; 270(3):1346-1360. PubMed ID: 36460875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
    Çınar E; Tel BC; Şahin G
    Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 Inflammasome Inhibition Prevents α-Synuclein Pathology by Relieving Autophagy Dysfunction in Chronic MPTP-Treated NLRP3 Knockout Mice.
    Ou Z; Zhou Y; Wang L; Xue L; Zheng J; Chen L; Tong Q
    Mol Neurobiol; 2021 Apr; 58(4):1303-1311. PubMed ID: 33169332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease.
    Pike AF; Longhena F; Faustini G; van Eik JM; Gombert I; Herrebout MAC; Fayed MMHE; Sandre M; Varanita T; Teunissen CE; Hoozemans JJM; Bellucci A; Veerhuis R; Bubacco L
    J Neuroinflammation; 2022 Feb; 19(1):50. PubMed ID: 35172843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases.
    Wu AG; Zhou XG; Qiao G; Yu L; Tang Y; Yan L; Qiu WQ; Pan R; Yu CL; Law BY; Qin DL; Wu JM
    Ageing Res Rev; 2021 Jan; 65():101202. PubMed ID: 33161129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.
    Chen L; Xue L; Zheng J; Tian X; Zhang Y; Tong Q
    Behav Brain Res; 2019 Jan; 356():483-489. PubMed ID: 29885849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.